Is the 1% rule applicable for CVD risk assessment in aeromedical practice?

Case presentation for Aviation Medicine Workshop Bahrain, 16 February 2023

Armine Danielyan, MD, PhD, Senior Medical Specialist of the Civil Aviation Committee of the Republic of Armenia

Case No1/ Air Traffic controller, 51 y. o. (male) on revalidation examination

- stable after myocardial infarction and coronary stenting event (mid LAD & IDES) 5 years ago.
- adequate physical activity, regularly taking medication (rosuvastatin+ ezetimibe, perindopril+ amlodipine 5/5 mg).
- Physical examination-no significant findings, BMI 29.
- Lab tests- CBC, electrolytes, uric acid, creatinine, liver enzymeswithin normal range
- Lipid profile- TC- 2.12 mmol/l, LDL-C 0.74 mmol/l, HDL 0.82 mmol/l, Triglycerides- 2.12 mmol/l, Glucose 5.15 mmol/l, HgA1C-5%

Cardiologist evaluation


- ECG- sinus rhythm 72 in 1', Left axis deviation, flattened T wave in I and aVL, partial RBBB
- Echocardiography-satisfactory left ventricular function with no important abnormality of wall motion, LVEF 50%.
- Coronarography after 5 years after the revascularizationdemonstrated- mid LAD stent was fully functioning, distant LAD- 30% narrowing, open angle artery OM1- 30% narrowing.
- Ds: IHD, I25.2 Old myocardial infarction, Z95. 5 Presence of coronary angioplasty implant, I11- Hypertension 1st degree, high risk
- Cardiologist evaluation- Low risk of repeated event.

SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe

- SCORE2—a new algorithm derived, calibrated, and validated to predict 10-year risk of first-onset CVD in European populations—enhances the identification of individuals at higher risk of developing CVD across Europe.
- SCORE2 provides risk estimates for the combined outcome of fatal and non-fatal CVD events.
- The SCORE2 charts available for CVD risk estimation in four European risk regions; countries were grouped into four risk regions according to their most recently reported WHO age- and sex-standardized overall CVD mortality rates per 100,000 population (ICD chapters 9, I00-I99).

Figure 2 Risk regions based on standardised cardiovascular disease mortality rates. Countries were grouped into four ...





Eur Heart J, Volume 42, Issue 25, 1 July 2021, Pages 2439–2454, https://doi.org/10.1093/eurheartj/ehab309



The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 3 SCORE2 charts for estimation of CVD risk in four European risk regions.



Α SCORE2 в SCORE2 <50 years 50-69 years <50 years 50-69 years 0-year risk of (fatal and non-fatal) <2.5% 10-year risk of (fatal and non-fatal) <5% <2.5% <5% CV events in populations at 2.5 to <7.5% 5 to <10% CV events in populations at 2.5 to <7.5% 5 to <10% low CVD risk ≥7.5% ≥10% moderate CVD risk ≥7.5% ≥10% Men Non-smoking Smoking Age Non-smoking Smoking Non-smoking Non-smoking Smoking Age Smoking 160-179 160-179 140-159 140-159 65 - 69 65 - 69 120-139 120-139 100-119 100-119 999 160-179 160-179 140-159 140-159 60 - 64 60 - 64 9 120-139 100-119 120-139 8 100-119 E 160-179 160-179 140-159 140-159 55 - 5 55 - 59 120-139 120-139 100-119 100-119 8 9 160-179 160-179 140-159 140-159 50 - 54 50 - 54 120-139 120-139 100-119 100-119 160-179 160-179 140-159 140-159 45 - 49 45 - 49 120-139 120-139 100-119 100-119 6 160-179 160-179 140-159 140-159 40 - 4 120-139 120-139 100-119 100-119 3.0- 4.0- 5.0- 6.0-3.0- 4.0- 5.0- 6.0 4.0- 5.0- 6.0-3.0- 4.0- 5.0- 6.0-3.0- 4.0- 5.0- 6.0-3.0- 4.0- 5.0- 6.0 3.0- 4.0- 5.0- 6.0-3.0- 4.0- 5.0- 6.0 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 Non-HDL cholesterol (mmol/L) Non-HDL cholesterol (mmol/L) 200 250 mg/cL mg/dL С D SCORE2 SCORE2 <50 years 50-69 years <50 years 50-69 years 10-year risk of (fatal and non-fatal) <2.5% <5% 10-year risk of (fatal and non-fatal) <2.5% <5% CV events in populations at 2.5 to <7.5% 5 to <10% 2.5 to <7.5% 5 to <10% CV events in populations at high CVD risk ≥7.5% ≥10% very high CVD risk >10% >7.5% Men Women Non-smoking Smoking Age Non-smoking Smoking Smoking Non-smoking Non-smoking Smoking Age 160-179 160-179 140-159 65 - 69 140-159 65 - 69 120-139 120-139 100-119 8 8 100-119 160-179 160-179 140-159 140-159 60 - 64 60 - 64 P 120-139 120-139 ¥ 100-119 160-179 160-179 140-159 140-159 55 - 59 55 - 59 120-139 120-139 100-119 8 8 100-119 160-179 160-179 140-159 140-159 50 - 54 50 - 54 120-139 8 a 120-139 100-119 4 100-119 160-179 160-179 140-159 140-159 45 - 49 45 - 49 120-139 120-139 100-119 100-119 160-179 160-179 140-159 140-159 40 - 44 120-139 120-139 100-119 100-119 3.0- 4.0- 5.0- 6.0-3.0- 4.0- 5.0- 6.0-3.0- 4.0- 5.0- 6.0-3.0- 4.0- 5.0- 6.0-3.0- 4.0- 5.0- 6.0-3.0- 4.0- 5.0- 6.0-3.0- 4.0- 5.0- 6.0-3.0- 4.0- 5.0- 6.0-3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 3.9 4.9 5.9 6.9 Non-HDL cholesterol (mmol/L) 200 250 Non-HDL cholesterol (mmol/L) 150 200 250 mg/dL mg/dL

Eur Heart J, Volume 42, Issue 25, 1 July 2021, Pages 2439–2454, <u>https://doi.org/10.1093/eurheartj/ehab309</u>




The content of this slide may be subject to copyright: please see the slide notes for details.

My calculations of CVD residual risk


https://uprevent.com/calculators/results /smartReach

SMART-REACH model

Personal Risk Profile ()





Colchicine 🕕



Residual Cardiovascular Risk calculation https://cambridgecardiaccare.com/calculator/

REACH Risk Calculator





Case No/2, Renewal of Class 1 certificate of a 59 y.o pilot.

- IHD, Coronary revascularization event after acute coronary syndrome 1 year ago (October 2021).
- Coronary Artery Bypass Graft (CABG) Surgery description-
- Vena−→OM
- N.T Vena \rightarrow _RCA
- Vena-seq \rightarrow Diagonal 1- \rightarrow Diagonal 2
- Mamaro-coronary shunt- \rightarrow LIMA-LAD
- Underwent Laparoscopic Cholecystectomy 3 months prior to cardiac event.

Case No2/ Physical examination and Lab tests

- Physical examination- otherwise normal, except BMI 30,
- Lab tests- CBC, Gluc, uric acid, creatinine, liver enzymes- within normal range, HgA1C 6.1%
- Lipid profile- TC 3.46 mmol/l, Triglycerides- 1.58 mmol/l, HDL 0.8, LDL 1.94 mmol/l
- ECG- Sinus rhythm, 70 per 1', CA left deviation, -T wave in aVL and I, flattened T wave in V_5 - V_6 .
- Extracranial vessel duplex examination- atherosclerosis of extracranial vessels, w/o occlusion.

Case No2/Cardiologist's evaluation/ suggested low risk of new events

- Echocardiography- no dilation of heart chambers, inferior and lateral mild hypokinesis, LVEF 50 %, Right ventricular contraction- Normal.
- 24H ECG- dominant sinus rhythm, prone to tachycardia, max 122, min 67. No ischemic episodes detected, no significant rhythm disturbances detected.
- Coronarography-1 year after revascularization- October 2022
- mid LAD 99% occlusion, Prox CX- 100 occlusion,
- Diag1, Diag2, Om1, PDA shunts are functioning appropriately, LAD shunt functioning appropriately
- Ds: IHD, I25.8 Other forms of chronic ischaemic heart disease, Z95. 5 Presence of coronary angioplasty graft, E66.0 Obesity first degree, alimentary genesis, Z90.4 Acquired absence of other parts of digestive tract (post cholecystectomy)

Calculator predictions:

uPrevent Calculator output

Date of calculation: 07/12/2022

CVD-free life-years:

Current lifetime risk of myocardial infarction, stroke or cardiovascular death

Age start treatment: 59

CVD-free life-expectancy: 76

10-years risk:

Current 10-year risk of myocardial infarction, stroke or cardiovascular death

Current risk: 22.87%


Reduction with treatment: 0%


U-Prevent+	CALCULATORS	MANUAL	ABOUI	co	NIACI	FN	
		SMAR	T-REAC	Hm	odel		
		Pers	onal Risk P	rofile (9		
Gender Age Geographic regio Current smoking Statin Dose Exctimibe PCSK9 inhibitor Antichrombotic treat Colchizine	y - Ata* 20*	ycars Ceronar Cerohar Peripher Disbe Hee	arosolarofic vascular lisease vartery disease vacular disease al artery disease tes mellitus rr. failure fibrillation	•	Systolic blood pressure Total cholasteral LDL-cholesterol Creatinin	120 mmHg 3.46 mmol/L 1.94 mmol/L 101 umol/L Adjust intate	
CVD-free life-years 10-years risk Lifetime risk Current 10-year risk of mycoandial infanction, stroke or cardiovascular ceath					Future treatment G		
0 5	10	15 20	25	30	Atorvastatin	~	
22.).0%		Dose 20 mg	~	
Current	risk ()	Reduction	with treatment ()		Fzetimihe FCSK9-inhibitor		
					Systolic blood pressure No treatment targe:	v	
					Antithrombotic treatment Aspirin or equivalent	~	
					Cokhicine 🕚	•	
					Intervention start age	years	
						Reset	

My calculations of CVD Residual risk

https://cambridgecardiaccare.com/calculator/ REACH Risk Calculator

Sex	Age
Male Female	55-59 ~
Smoker?	Diabetes?
Yes No	Yes No
BMI Less than or equal to 20kg/m ² Greater than 20kg/m ²	Number of affected vascular beds including CAD, PAD and cerebrovascular disease 3 v
CV event in the previous year?	Congestive Heart Failure?
Yes No	Yes No
Atrial Fibrillation?	Currently on Statin therapy?
Yes No	Yes No
Currently on Aspirin?	Location of patient's current residence
Yes No	Eastern Europe/middle east ~





- Aeromedical evaluation-Class 1 with OML.
- CVD event free life expectancy- 76 and cardiologists assurance about relatively small risk for repeated event- helped to take decision.
- Would you agree?

Toros Roslin miniature, a page from a 13th century gospel,

written in Hromkla, fortress of Cilician Armenia, that served as the residence of the Catholicos of All Armenians from 1149 till 1292.

